Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

4 terminated/withdrawn out of 8 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
4(50.0%)
Phase 1
2(25.0%)
Phase 3
2(25.0%)
8Total
Phase 2(4)
Phase 1(2)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT02719990Phase 2Terminated

Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)

Role: lead

NCT02339090Phase 3Completed

Long-Acting Growth Hormone in Children Compared to Daily rhGH

Role: lead

NCT01718041Phase 1Completed

Versartis Trial in Children to Assess Long-Acting Growth Hormone

Role: lead

NCT02526420Phase 2Completed

Versartis International Trial in Adults With Long-Acting Growth Hormone

Role: lead

NCT02413138Phase 2Terminated

Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)

Role: lead

NCT02068521Phase 2Terminated

Versartis Long-Term Safety Study of Somavaratan

Role: lead

NCT03145831Phase 3Terminated

A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency

Role: lead

NCT01359488Phase 1Completed

VRS-317 in Adult Subjects With Growth Hormone Deficiency

Role: lead

All 8 trials loaded